A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Brazikumab (Primary) ; Brazikumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Allergan; MedImmune
- 24 Aug 2017 This study has been suspended in Bulgaria as per Eudra record.
- 31 Mar 2017 Planned End Date changed from 1 Sep 2019 to 18 Jun 2019.
- 31 Mar 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.